EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vanda Pharmaceuticals's enterprise value is $-102.7 Mil.
Vanda Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.9 Mil. Therefore, Vanda Pharmaceuticals's EV-to-EBITDA for today is 9.38.
The historical rank and industry rank for Vanda Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
VNDA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -188.1 Med: -6.2 Max: 441.02
Current: 9.38
During the past 13 years, the highest EV-to-EBITDA of Vanda Pharmaceuticals was 441.02. The lowest was -188.10. And the median was -6.20.
VNDA's EV-to-EBITDA is ranked better than 52.12% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs VNDA: 9.38
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Vanda Pharmaceuticals's stock price is $4.63.
Vanda Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.052. Therefore, Vanda Pharmaceuticals's PE Ratio for today is 89.04.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Vanda Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for Vanda Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vanda Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanda Pharmaceuticals EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vanda Pharmaceuticals's EV-to-EBITDA falls into.
Vanda Pharmaceuticals EV-to-EBITDA Calculation
Vanda Pharmaceuticals's EV-to-EBITDA for today is calculated as:
Vanda Pharmaceuticals's current Enterprise Value is $-102.7 Mil.
Vanda Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Vanda Pharmaceuticals's PE Ratio for today is calculated as:
Vanda Pharmaceuticals's share price for today is $4.63.
Vanda Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.052.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Vanda Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Vanda Pharmaceuticals (Vanda Pharmaceuticals) Business Description
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VNDA has been successfully added to your 